Institut Bergonié
Accueil Clinical research Hervé Bonnefoi
Envoyer Imprimer PDF


Group members and Contact details

 

Hervé  Bonnefoi,  MD,  is  a  professor  of  Medical  Oncology  at  the  University  of  Bordeaux, and consultant  at the Bergonié  Cancer Institute  in Bordeaux.  He obtained  a privat-­‐docent  in Geneva Medical University.

Professor Bonnefoi received his medical degree from the University of Grenoble Medical School in Grenoble, France, and completed further training at the University of Geneva, Switzerland; and the Royal Marsden Hospital in London, United-­‐Kingdom.

 
bonnefoi h 2015 

His  research  interests  focus  on  the  neoadjuvant  and  post-­‐neoadjuvant  treatment  of  breast  cancer as well as the identification  of targetable  genomic aberrations  in patients whose tumors did not achieve a pathological complete response after neoadjuvant chemotherapy; his aim is to identify mechanisms of resistance to hormonal therapy and to develop preclinical breast cancer models including molecular apocrine tumors. These studies are being conducted in collaboration with Prof. Richard Iggo within the INSERM unit located in Bergonié Institute and with the Karolinska Institute in Stockholm, Sweden; the Sanger Institute in Cambridge, United-­‐Kingdom; and several academic research  groups  (EORTC:  European  Organisation  for  Research  and  Treatment  of  Cancer;  IBCSG: International Breast Cancer Study Group; UCBG: Unicancer Breast Intergroup).

Professor  Bonnefoi  is  a  member  of  the  European  Breast  Cancer  Conference  (EBCC)  Scientific Committee (since 2000), European Society of Medical Oncology (ESMO Scientific) Committee (since 2016), and St Gallen breast cancer Consensus Meeting expert panel (since 2011). He was a member of the American Society of Clinical Oncology (ASCO) Scientific Committee (2009-­‐2011;  track-­‐leader in  2011) and Educational  Program  Committee  (2011). He is a past chair of the European  EORTC Breast Cancer Group and the UNICANCER French Breast Cancer Intergroup (UCBG). He is a member of the steering committee of these two research groups dedicated to breast cancer.

A  reviewer  for  several  peer-­‐reviewed   journals,  Professor  Bonnefoi  is  author  or  coauthor  of numerous articles that have appeared in Annals of Oncology, Breast Cancer Research, Breast Cancer Research and Treatment, European Journal of Cancer, Lancet, Lancet Oncology, Nature Medicine, New England Journal of Medicine, and Oncogene among others.

Publications since 2015

1.     Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, L'Haridon T, Cottu P, Abadie-­‐Lacourtoisie S, You B, Mousseau M, Dauba J, Del Piano F, Desmoulins I, Coussy F, Madranges M, Grenier J, Bidard FC, Proudhon C, MacGrogan G, Orsini C, Pulido M, Gonçalves A. A phase II trial of abiraterone acetate plus prednisone in patients with triple-­‐negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-­‐1). Ann Oncol 2016;27:812-­‐8  

2.      Richard E, Grellety T, Velasco V, MacGrogan G, Bonnefoi H, Iggo R. The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours. J Pathol 2016 (in press)

3.      Fei F, Messina C, Slaets L, Chakiba C, Camerom D, Bogaerts J, Bonnefoi H. Tumour size is the only predictive factor of distant recurrence after pathological complete response (pCR) to neoadjuvant chemotherapy in Hervé Bonnefoi, MD Professor of Medical Oncology University of Bordeaux Consultant  Bergonié Cancer Institute Bordeaux, France patients with large operable or locally advanced breast cancers: a sub-­‐study of EORTC 10994/BIG-­‐001 Phase III Trial. Eur J Cancer 2015; 51:301-­‐9

4.     Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-­‐Bouvet L, Zaman K, Matos E, Petit T, Bodmer A, Quenel-­‐Tueux N, Chakiba C, Vuylsteke P, Jerusalem G, Brain E, Tredan O, Messina C, Slaets L, Cameron D. Neoadjuvant  treatment with docetaxel plus lapatinib, trastuzumab,  or both followed by an anthracycline  based chemotherapy  in HER2-­‐positive breast cancer: results of the randomised phase II EORTC 10054 study. Ann Oncol 2015; 26:325-­‐32

5.       Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, André F. Precision medicine for metastatic breast cancer-­‐limitations and solutions. Nat Rev Clin Oncol 2015;12:693-­‐704

6.     Francis P, Regan M, Fleming G, Láng I, Eva Ciruelos E, Bellet M, Bonnefoi H, Climent M, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer E, Rabaglio-­‐ Poretti M, Maibach R, Ruepp B, Giobbie-­‐Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant Ovarian Function Suppression in Premenopausal  Breast Cancer. N Engl J Med 2015;372:436-­‐46

7.     Francis P, Regan M, Fleming G, Láng I, Eva Ciruelos E, Bellet M, Bonnefoi H, Climent M, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer E, Rabaglio-­‐ Poretti M, Maibach R, Ruepp B, Giobbie-­‐Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant Ovarian Function Suppression in Premenopausal  Breast Cancer. N Engl J Med 2015;372:436-­‐46

8.     Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer CE, Jr., Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-­‐Poretti M, Maibach R, Ruepp B, Giobbie-­‐Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA. Adjuvant Exemestane with Ovarian Suppression in Premenopausal  Breast Cancer. N Engl J Med 2014

9.     Bonnefoi H, Litiere S, Piccart M, Macgrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C, Bodmer A, Zaman K, Cufer T, Campone M, Luporsi E, Malmstrom P, Werutsky G, Bogaerts J, Bergh J, Cameron DA. Pathological complete response after neoadjuvant chemotherapy  is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-­‐step approach analyses from the EORTC 10994/BIG 1-­‐00 phase III trial. Ann Oncol 2014 ; 6: 1128-­‐36

10.   André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-­‐Triki M, Lacroix L, Cohen P, Gentien D, Adelaide J, Dalenc F, Goncalves A, Levy C, Ferrero JM, Bonneterre J, Lefeuvre C, Jimenez M, Filleron T, Bonnefoi H. Array CGH and DNA sequencing for treatment decision in metastatic breast cancer: A multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014 ; 15: 267-­‐274

11.   Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE, Jr., Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological Complete Response in Breast Cancer: CTNeoBC Pooled-­‐Analysis. Lancet 2014

12.   Iggo R, Rudewicz J, Monceau E, Sevenet N, Bergh J, Sjoblom T, Bonnefoi H. Validation of a yeast functional assay for p53 mutations using clonal sequencing. J Pathol 2013 ; 231 : 441-­‐8

13.   Bonnefoi H, Piccart M, Bogaerts J et al. TP53 status for prediction of sensitivity to taxane versus non-­‐taxane neoadjuvant chemotherapy  in breast cancer (EORTC 10994/BIG 1-­‐00): a randomised phase 3 trial. Lancet Oncology 2011; 12:527-­‐539

14.   Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M. A stroma-­‐ related gene signature predicts resistance to neoadjuvant chemotherapy  in breast cancer. Nat Med 2009;15(1):68-­‐74

15.   Farmer P, Bonnefoi H, Becette V, Tubiana-­‐Hulin M, Fumoleau P, Larsimont D, MacGrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R. Identification  of molecular apocrine breast tumors by microarray analysis. Oncogene 2005; 24:4660-­‐71

 

bergonewsn23

Faire un don

ATRIVM

Culture et santé



Editorial

Federation des CLCC

Associations

Kiosque